Evidence map›Paper›PMID 38463590›Full record

ArticleAmerican journal of translational research2024

Complex phenotypic heterogeneity of combined hepatocellular-cholangiocarcinoma with a homogenous

Sumie Ohni, Hiromi Yamaguchi, Yukari Hirotani, Yoko Nakanishi, Yutaka Midorikawa, Masahiko Sugitani, Tomohiro Nakayama, Makoto Makishima, Mariko Esumi

Abstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sumie OhniDivision of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine Tokyo, Japan.
Hiromi YamaguchiDivision of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine Tokyo, Japan.
Yukari HirotaniDivision of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine Tokyo, Japan.
Yoko NakanishiDivision of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine Tokyo, Japan.
Yutaka MidorikawaDepartment of Surgery, Nihon University School of Medicine Tokyo, Japan.
Masahiko SugitaniDivision of Human Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine Tokyo, Japan.
Tomohiro NakayamaDivision of Clinical Laboratory Medicine, Department of Pathology and Microbiology, Nihon University School of Medicine Tokyo, Japan.
Makoto MakishimaDivision of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine Tokyo, Japan.
Mariko EsumiDivision of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To clarify the mechanism underlying the development and poor prognosis of combined hepatocellular-cholangiocarcinoma (cHCC-CCA), we characterized liver cancer driver mutations and poor prognostic markers in both the HCC and intrahepatic CCA (iCCA) components of a cHCC-CCA tumor. The telomerase reverse transcriptase (

Indexed as

Combined hepatocellular-cholangiocarcinomadedifferentiationdigital PCRimmunohistochemistryKi67p53phenotypic heterogeneityTERT promoter mutationTERT proteintransdifferentiation

Identifiers

PMID38463590
PMCPMC10918120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.